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Serum Vascular Endothelial Growth Factor and COX-2/5-
LOX Inhibition in Advanced Non-small Cell Lung Cancer
Cancer and Leukemia Group B 150304
Martin J. Edelman, MD,* Lydia Hodgson, MS,† Xiaofei Wang, PhD,† Robert Christenson, MD,*
Scott Jewell, PhD,‡ Everett Vokes, MD,§ and Robert Kratzke, MD
Introduction: Eicosanoids, including PGE-2 and 5-HETE, can
increase levels of plasma vascular endothelial growth factor
(VEGF). Overexpression of COX-2 or 5-LOX increases levels of
PGE-2 and 5-HETE, respectively. Elevated levels of VEGF are
common in patients with non-small cell lung cancer (NSCLC). We
prospectively measured VEGF in serum collected from patients
enrolled in Cancer and Leukemia Group B 30203, a randomized
phase II study of eicosanoid modulation in addition to chemotherapy
in patients with advanced NSCLC, to determine whether these levels
had prognostic significance and whether they correlated with COX-2
expression and/or responded to inhibition of COX-2 or 5-LOX.
Methods: Pre- and post-treatment serum was collected from pa-
tients enrolled in CALGB 30203. Serum VEGF levels were deter-
mined using enzyme-linked immunosorbent assay methodology.
Statistical analyses were performed to determine the correlation
between pretreatment serum VEGF levels and time of overall
survival. Pretreatment formalin fixed tissue was stained for 5-LOX
and COX-2 by immunohistochemistry.
Results: The median baseline VEGF level was 502 pg/ml (range,
55–3453 pg/ml). Dichotomized serum VEGF levels at median in-
versely correlated with survival time (p  0.008), as did VEGF
levels as a continuous variable in multivariate analysis (p  0.035).
VEGF levels were significantly correlated neither with baseline
COX-2 expression (Pearson r 0.1524, p 0.271) nor with 5-LOX
expression. Treatment with COX-2 or 5-LOX inhibitors did not alter
the levels.
Conclusion: These data indicate that elevated serum VEGF is a
negative prognostic variable in NSCLC. VEGF levels are neither
correlated with baseline tumor COX-2 expression nor do they
respond to COX-2 and/or 5-LOX inhibition plus chemotherapy.
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Angiogenesis plays a pivotal role in cancer developmentand progression. Central to angiogenesis is vascular en-
dothelial growth factor (VEGF), the primary stimulus to the
formation of new blood vessels.1 VEGF production may be
induced through multiple pathways. Arachadonic acid metab-
olites (eicosanoids) produced through increased levels of
COX-2 or 5-LOX expression are known to stimulate VEGF
production. COX-2 metabolites, specifically PGE-2, have
been documented to be associated with increased VEGF
levels and their phenotypic manifestations such as microves-
sel density in a range of malignancies, including head and
neck, colorectal, and lung cancer.2–4 Laboratory models have
demonstrated that inhibition of COX-2 can decrease angio-
genesis, as documented by diminished microvessel density.5
Arachadonic acid may also be metabolized through lipoxy-
genases including 5, 10, or 12 lipoxygenase. 5-LOX expres-
sion has also been associated with increased VEGF levels in
mesothelioma and colorectal carcinoma.6,7
CALGB 30203 tested the concept of eicosanoid inhi-
bition in advanced lung cancer.8 The hypothesis was that
eicosanoid inhibition in addition to standard chemotherapy
would potentially increase progression-free survival. Further-
more, the concept of single versus double pathway inhibition
was tested with inhibitors of COX-2 and 5-LOX as both
single agents and in combination. Based on preclinical ob-
servations that COX-2 and 5-LOX inhibitors might exert their
effects through inhibition of VEGF; CALGB 150304 was an
embedded companion study with the objective of exploring
whether levels of VEGF correlated with COX-2 and 5-LOX
expression and with outcome. To evaluate this hypothesis,
serum specimens were requested before institution of therapy
and after the first and second courses of treatment. An
additional objective of this study, determining whether levels
of cytokeratin fragments correlate with response and out-
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come, has been separately reported.9 This study complies
with guidelines regarding the reporting of tumor markers.10
The study was approved by the Institutional Review Boards
of all participating institutions, and all patients provided
written informed consent.
METHODS
Patients with advanced non-small cell lung cancer
(NSCLC) (stage IIIb [pleural effusion]/IV) with perfor-
mance status 0 to 2, and normal organ function were
randomized to receive chemotherapy (carboplatin area
under the curve 5.5, day 1 and gemcitabine 1000 mg/m2
day 1, 8 with one of three eicosanoid modulating regimens:
zileuton 600 mg four times daily, celecoxib 400 mg twice
daily, or both agents.8
Specimens were collected in 7 ml red top tubes, gently
inverted five times to mix completely. After 30 minutes, the
tubes were spun for 10 minutes at 1100 to 1300 g in swinging
head rotor centrifuges. After centrifugation, serum was re-
moved and placed in a polypropylene tube and frozen to at
least 20°C or colder. Specimens were shipped within 30
days on dry ice by overnight express to the CALGB Pathol-
ogy Coordinating Office at the Ohio State University. Ali-
quots were sent to the laboratory of one of the investigators
(R.C.) on dry ice and kept at 80°C until analysis. The
investigator was blinded to the identities, treatment alloca-
tion, and outcomes. VEGF was measured using a commer-
cially available enzyme-linked immunosorbent assay (R&D
Systems, Minneapolis, MN). All specimens were run on first
thaw only and in duplicate. The lower limit for detection of
VEGF was 9.0 pg/mL. The intra-assay precision was 6.7% at
53.7 pg/ml, 4.5% at 235 pg/ml, and 5.15% at 910 pg/ml.
Interassay variation was 8.8% at 64.5 pg/ml, 7.0% at 250
pg/ml, and 6.2% at 1003 pg/ml.
Statistical Analysis
Patient registration and clinical data collection were
managed by the CALGB Statistical Center. The CALGB
Pathology Coordinating Office at the Ohio State University
processed the specimens. Serum VEGF assays were con-
ducted at the University of Maryland. Assays were conducted
without knowledge of clinical outcomes. The statistical anal-
yses were performed by CALGB statisticians using SAS
version 9.1 (SAS, Cary, NC). The balance of demographic
and clinical variables across study arms were tested by 2
tests for categorical variables and Wilcoxon rank sum tests
for continuous variables. Kaplan-Meier curves were used to
characterize survival. Median survival and its 95% confi-
dence intervals were computed. Log-rank tests were used to
test the survival difference between study arms.
To reduce the influence of potentially skewed data,
serum VEGF values were natural-log-transformed at base-
line, cycle 1, and cycle 2. The relationship to VEGF levels as
continuous or binary variable was evaluated with Cox regres-
sion analysis in both univariate and multivariate models and
the proportional hazards assumption was tested for all mod-
els. Logistic regression was used to evaluate the association
between tumor response and VEGF levels. In multivariate
regression analyses, stepwise variable selection was used to
select significant predictive factors. The association with
COX-2 and 5-LOX indices was computed for continuous
VEGF levels using Pearson correlation coefficient and for
dichotomized VEGF levels using Spearman rank correlation
coefficient. All p values were two-sided and no adjustment
for multiple comparisons was made.
RESULTS
CALGB 30203 enrolled 140 patients in under 1 year.
Neither the population as a whole nor any of the three arms
achieved the predetermined criterion for a successful out-
come. These results have been previously reported.8 Blood
specimens were received on 88 patients (63%). The charac-
teristics of this patient population are presented in Table 1.
The median baseline VEGF level was 502 pg/ml (range,
55–3453 pg/ml) (Table 2). Baseline VEGF levels were sig-
nificantly associated with overall survival when dichotomized
at the median (p  0.008; Figure 1). Higher baseline VEGF
was associated with inferior survival. After log transforma-
tion, higher baseline VEGF levels as a continuous variable
were also significantly associated with worse overall survival
both as a single predictor (p  0.057) and when adjusted for
age and performance status in multivariate analysis (p 
0.035; Table 3 and Figure 1). However, VEGF levels were
not associated with failure-free survival. Additionally, the
TABLE 1. Baseline Patient Characteristic (n  88)
Characteristics
Arm A
(n  22),
n (%)
Arm B
(n  31),
n (%)
Arm C
(n  35),
n (%)
Total
(n  88),
n (%)
Gender
Male 15 (68) 18 (58) 21 (60) 54 (61)
Female 7 (32) 13 (42) 14 (40) 34 (39)
Age (yr)
40–49 1 (5) 2 (6) 2 (6) 5 (6)
50–59 4 (18) 18 (58) 13 (37) 35 (40)
60–69 11 (50) 7 (23) 12 (34) 30 (34)
70–79 5 (23) 3 (10) 6 (17) 14 (16)
80 1 (5) 1 (3) 2 (6) 4 (5)
Median (min, max) 62 (41, 80) 57 (47, 80) 61 (48, 81) 60 (41, 81)
Race
White 20 (91) 27 (87) 28 (80) 75 (85)
Black 1 (5) 4 (13) 5 (14) 10 (11)
Other 1 (5) 0 (0) 2 (6) 3 (3)
Histology
Adenocarcinoma 11 (50) 16 (52) 17 (49) 44 (50)
Squamous 6 (27) 6 (19) 9 (26) 21 (24)
Undifferentiated 4 (18) 7 (23) 8 (23) 19 (22)
Other 1 (5) 2 (6) 1 (3) 4 (5)
Performance status
0 4 (18) 8 (26) 15 (43) 27 (31)
1 17 (77) 23 (54) 15 (43) 55 (63)
2 1 (5) 0 (0) 5 (14) 6 (7)
Stage
IIIB 2 (9) 2 (6) 3 (9) 7 (8)
IV 18 (82) 27 (87) 31 (89) 76 (86)
Recurrent 2 (9) 2 (6) 1 (3) 5 (6)
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reduction in VEGF from baseline was not significantly asso-
ciated with overall survival (p  0.730), failure-free survival
(p  0.722; Table 3), or radiologic response (Table 4).
In the primary report of this trial, we presented data
demonstrating that COX-2 expression was a negative prog-
nostic factor but a positive predictive factor for benefit from
celecoxib. Using immunohistochemistry of 80 tissue speci-
mens, we demonstrated that patients with expression of
COX-2 had a worse overall survival than those who did not
express COX-2 or had minimal levels of COX-2 expression
(hazards ratio [HR] for moderate expression (index of 4,
HR  2.68, p  0.018). More importantly, analysis of
patients receiving celecoxib (with or without zileuton) whose
tumors expressed COX-2 (moderate to high expression, index
FIGURE 1. CALGB 30203: Overall survival
by baseline vascular endothelial growth fac-
tor (VEGF).
TABLE 2. VEGF Levels (pg/ml)
Markers Arm A (n  22) Arm B (n  31) Arm C (n  35) Total (n  88)
VEGF baseline 415, 457, (57, 1682) 509, 695, (55, 2889) 540, 794, (61, 3453) 502, 675, (55, 3453)
VEGF cycle 1 331, 504, (69, 1645) 408, 578, (32, 2634) 476, 751, (123, 2051) 418, 629, (32, 2634)
VEGF cycle 2 221, 246, (40, 694) 299, 393, (34, 1135) 335, 585, (92, 1538) 305, 435, (34, 1538)
Log VEGF baseline 6.0, 5.9, (4.0, 7.4) 6.2, 6.2, (4.0, 8.0) 6.3, 6.4, (4.1, 8.1) 6.2, 6.2, (4.0, 8.1)
Log VEGF cycle 1 5.8, 5.9, (4.2, 7.4) 6.0, 5.9, (3.5, 7.9) 6.2, 6.3, (4.8, 7.6) 6.0, 6.1, (3.5, 7.9)
Log VEGF cycle 2 5.4, 5.3, (3.7, 6.5) 5.7, 5.7, (3.5, 7.0) 5.8, 6.0, (4.5, 7.3) 5.6, 5.7, (3.5, 7.3)
Values are expressed as Median, Mean, (minimum, maximum).
VEGF, vascular endothelial growth factor.
TABLE 3. Association of VEGF Level with Overall Survival and Failure-Free Survival
Parameter
Overall Survival Failure-Free Survival
p
Hazard Ratio
95% CI p
Hazard Ratio
95% CI
Univariate analysis
Log (VEGF baseline) 0.057 1.32 (0.99, 1.77) 0.491 0.91 (0.71,1.18)
Multivariate analysisa
Log (baseline VEGF) 0.035 1.42 (1.03,1.97) 0.843 0.97 (0.72, 1.32)
Log (baseline VEGF)-Log (VEGF cycle 1) 0.730 0.94 (0.64,1.37) 0.722 0.93 (0.63 1.38)
Performance (1–2 vs. 0) 0.084 1.58 (0.94,2.66) 0.695 1.11 (0.67, 1.84)
Age (65 yr vs. 65 yr) 0.077 1.59 (0.95,2.66) 0.438 1.22 (0.74, 2.01)
a Log baseline VEGF and Log (baseline VEGF)–Log (VEGF cycle 1) were forced into the final model with performance status, stage,
age, treatment arm, sex, race, and histology as potential variables to be selected using stepwise algorithm with entry level of 0.10 and stay
level of 0.10. Of 88 patients in the analysis, 78 patients were died; 85 failed (died or disease progressed).
CI, confidence interval; VEGF, vascular endothelial growth factor.
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4, HR 0.420, p  0.039) had a superior outcome com-
pared with patients with expression who did not receive
celecoxib. Furthermore, the higher the degree of COX-2
expression, the greater the degree of benefit from celecoxib.
Given the above results, we explored whether there was
any correlation between VEGF levels or change in levels and
COX-2 expression. We also evaluated whether there was any
relationship to 5-LOX expression. In addition, we wished to
determine whether celecoxib had any influence on VEGF
levels, including an analysis as to whether there was any
relationship with COX-2 expression in the tumor. These
analyses are limited by small numbers and incomplete over-
lap (n 54) of those who had both tissue specimens adequate
for COX-2 or 5-LOX expression (n  83) and adequate
serum samples (n  88). There was a statistically insignifi-
cant trend for a positive correlation between baseline VEGF
and COX-2 expression. The Pearson correlation coefficients
between baseline VEGF and COX-2 was 0.1524 (p 0.271),
and the Spearman correlation coefficient between baseline
VEGF and COX-2 as 4 versus less than 4 was also not
significant at 0.1260 (p  0.364).
A possible mechanism for COX-2 and/or 5-LOX inhi-
bition is suppression of VEGF. We did not find any indication
of a relationship between baseline tumor expression of either
COX-2 or 5-LOX and VEGF levels or response to the
inhibitor, Table 5. We found that the degree of decline in
VEGF levels (baseline-cycle 1) was not significantly related
to COX-2 index with a Pearson correlation efficient of
0.1443 (p  0.298).
Similarly, the Spearman rank correlation coefficient
was 0.1235 (p  0.374) for VEGF decline and COX-2 4
versus less than 4, indicating again no significant association
between COX-2 index and the decline in VEGF. In addition,
comparing patients who received celecoxib (arms B, C) with
those who did not (arm A), there was no significant difference
in VEGF decline (p  0.422). The relationship between
baseline COX-2 expression, treatment with celecoxib and
change in VEGF levels was also evaluated. For patients with
COX-2 4 (n  18), no significant differences in changes of
VEGF levels were observed between patients who did or did
not receive celecoxib (p  0.863). Similar results were found
for 5-LOX.
DISCUSSION
Inhibition of angiogenesis has now been validated as an
effective anticancer strategy in general and in lung cancer
specifically. The use of the anti-VEGF antibody bevacizumab
has been demonstrated to improve outcome in terms of
progression-free survival in two trials and overall survival in
one study.11,12 Small molecule inhibitors of the VEGF recep-
tor have also demonstrated some activity, though the results
of randomized studies have been mixed.13
Another approach to angiogenesis inhibition is the use
of agents that decrease VEGF production directly or indi-
rectly. There is preclinical evidence that eicosanoid modula-
tors reduce VEGF production.14 Others have found that
chemotherapy alone was associated with a decrease in VEGF
levels.15 We did not demonstrate that eicosanoid inhibition in
addition to chemotherapy suppressed VEGF levels, even in
patients with response or with high COX-2 expression. This
finding does not exclude an interrelationship of COX-2 and
VEGF as in some models it is VEGF that stimulates the
production of COX-2.16 However, we did demonstrate the
negative prognostic value of baseline serum VEGF levels,
which has been seen in both the early (i.e., preoperative) and
metastatic settings.17 This finding is somewhat different from
the results of the Eastern Cooperative Oncology Group,
which demonstrated a correlation between baseline VEGF
levels and failure free but not overall survival.18 In the
Eastern Cooperative Oncology Group trial, there was a trend
toward poorer overall survival with elevated VEGF levels.
In summary, this study confirms the negative prognos-
tic value of serum VEGF in patients with advanced non-small
cell lung cancer. However, it failed to demonstrate that
eicosanoid modulation in addition to chemotherapy could
reduce VEGF production. In addition, there was no correla-
tion demonstrated between VEGF levels and COX-2 expres-
sion. Although these results are limited by the small numbers
TABLE 5. Correlation of VEGF Levels with COX-2 and 5-LOX
Correlation
VEGF and COX-2 (n  54) VEGF and 5-LOX
Cox-2 Indexa
High Cox-2 vs.
Low (>4 vs. <4)b 5-LOX Indexa
High 5-LOX vs.
Low (>6 vs. <6)b
Baseline VEGF 0.1127 (p  0.417) 0.1260 (p  0.364) 0.1534 (p  0.268) 0.2178 (p  0.114)
Log (baseline VEGF) 0.1524 (p  0.271) 0.1260 (p  0.364) 0.2049 (p  0.137) 0.2178 (p  0.114)
Decrease of VEGF from baseline to cycle 1 0.1232 (p  0.375) 0.1210 (p  0.384) 0.1179 (p  0.396) 0.1156 (p  0.405)
Diff_Log baseline cycle 1 0.1443 (p  0.298) 0.1235 (p  0.374) 0.1469 (p  0.289) 0.1378 (p  0.320)
a Pearson correlation coefficients.
b Spearman correlation coefficients.
VEGF, vascular endothelial growth factor.
TABLE 4. Correlation of Radiologic Response and VEGF
p
Odds Ratio
(95% CI)
Log (baseline VEGF) 0.2402 1.418 (0.792–2.542)
Log (baseline VEGF)  Log (VEGF
cycle 1)
0.2288 1.496 (0.776–2.882)
a If complete response or partial response, response  1; else response  0.
CI, confidence interval; VEGF, vascular endothelial growth factor.
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of patients, it seems likely that the beneficial results of
COX-2 inhibition in addition to chemotherapy demonstrated
in the subset of patients with high levels of COX-2 expression
was mediated by a process other than VEGF suppression.
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